Healthcare Innovation is Evolutionary
The pandemic may have put an end to many things, but it only accelerated early stage funding into healthcare startups. ...
Mens Rea & Dr. Gokal
A Houston physician finds himself facing the ire of the law after he administered vaccines to acquaintances not scheduled to ...
The Importance of Credibility
Rule of law demands equal treatment under the law. Yet when physicians are accused of crimes, rule of law often ...
When Economy Becomes Biology
Under the new COVID-19 relief package, the federal government provides long overdue support for those suffering in the midst of ...
What Happened to COVID-19 Testing?
In recent weeks COVID-19 testing has reduced significantly, which many attribute to the rise in vaccinations. But positivity rates are ...
Patient Cyber Narratives
Healthcare will become more decentralized and populist post-pandemic. With patients relying upon digital and internet-based tools to seek medical care ...
Taxing Healthcare Behavior
If we have learned anything from the pandemic, it is that healthcare is linked to all aspects of society, and ...
The Pandemic May End Soon – That’s the Problem
With the pandemic ending, we are beginning to predict the future of healthcare and society. But the future never follows ...
Pandemic’s Ecological Fallacy
The pandemic ushered in clinical studies that have changed healthcare policy. But the pace of publications also led to studies ...
War Elephants of Healthcare
The original battle tanks of antiquity, war elephants were famed for the terror they inflicted on the battlefield. And equally ...
Anatomy of a DEA Investigation
As the opioid epidemic rages on, DEA agents intensify their efforts to curtail the diversion of prescription medications.
Medical Devices are for the Startups
Most new medical devices are designed and developed by startups, only to be acquired by larger medical device corporations when ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more